Our research into rare cancers
For the past 120 years, we’ve been making discoveries that have saved countless lives. But we have so much more to do. Our strategy sets out how we'll accelerate progress towards a better future.
Our research is saving lives
Together, rare cancers make up more than 20% of all cancer cases. We’ve contributed to several advances for people with rare cancers. We ran some of the first trials for people with uveal melanoma and neuroendocrine tumours, and showed that the drug Glivec was effective for some advanced gastro-intestinal stromal tumours (GIST). And we set up and continue to support the International Rare Cancers Initiative, which is developing clinical trials worldwide to find new treatments for rare cancers.